ATI-450, an investigational MK2 inhibitor, is well tolerated and demonstrated clinical activity in patients with mod/severe RA: A 12-week phase 2a, randomized, investigator/patient-blind study investigating the safety, tolerability, PK and PD of ATI-450+MTX vs PBO+MTX in MTX IR patients

Category Primary study
ConferenceArthritis and Rheumatology
Year 2021
This article has no abstract
Epistemonikos ID: c739a240b37a643206d2618ff8f4cd187b445d76
First added on: Apr 30, 2026